← Eichor
Study identifier: NCT07401615 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

Condition: Non Small Cell Lung Cancer · Pulmonary Stereotactic Radiotherapy  ·  Sponsor: Istituto Clinico Humanitas

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time. Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.

This description comes directly from the study's public registry record.

Talk to the study team

Davide Franceschini, MD, radiation oncologist  ·  +39 0282247428  ·  davide.franceschini@cancercenter.humanitas.it

Laura Bonavita, master degree  ·  +39 0282247026  ·  laura.bonavita@humanitas.it

Always discuss trial participation with your own doctor first.

Locations (11)

AST Papa Giovanni XXIIIBergamo, Bergamo, ItalyRecruiting
Radiotherapy Department, Ospedale Bellaria Carlo Alberto PizzardiBologna, Bologna, ItalyNot Yet Recruiting
REM RadioterapiaCatania, Catania, ItalyNot Yet Recruiting
Radiation oncology unit, Ospedale San RaffaeleMilan, Milano, ItalyNot Yet Recruiting
Radiotherapy Department, Istituto Europeo di OncologiaMilan, Milano, ItalyNot Yet Recruiting
IRCCS Humanitas Research HospitalRozzano, Milano, ItalyRecruiting
Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. PascaleNaples, Napoli, ItalyNot Yet Recruiting
Centro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia OncologicaRoma, Roma, ItalyNot Yet Recruiting
Radioterapia Oncologica - Ospedale dell'AngeloVenezia, Venezia, ItalyNot Yet Recruiting
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care CenterNegrar, Verona, ItalyNot Yet Recruiting
AOUI Verona, DAI Chirurgia e Oncologia - Radioterapia OncologicaVerona, Verona, ItalyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07401615